Precision BioSciences (NASDAQ:DTIL) Earns “Buy” Rating from HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $60.00 target price on the stock.

Precision BioSciences Stock Down 0.2%

DTIL stock opened at $4.64 on Wednesday. Precision BioSciences has a one year low of $3.61 and a one year high of $13.44. The stock has a market capitalization of $48.95 million, a PE ratio of 77.35 and a beta of 1.55. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The company has a fifty day moving average of $4.98 and a 200-day moving average of $5.39.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $5.00 million. As a group, analysts expect that Precision BioSciences will post -1.23 EPS for the current year.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds have recently added to or reduced their stakes in the business. Miller Financial Services LLC purchased a new position in Precision BioSciences during the 1st quarter valued at about $48,000. Commonwealth Equity Services LLC purchased a new position in Precision BioSciences during the 4th quarter valued at about $48,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Precision BioSciences by 22.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock valued at $59,000 after acquiring an additional 2,805 shares in the last quarter. Samalin Investment Counsel LLC purchased a new position in Precision BioSciences during the 4th quarter valued at about $59,000. Finally, XTX Topco Ltd purchased a new position in Precision BioSciences during the 4th quarter valued at about $67,000. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.